semicarbazide

Semicarbazide hydrochloride is a urea derivative that binds to copper or iron in cells to produce antiviral, anti-infective and anti-tumor effects.

Semicarbazide-13C-15N2 Hydrochloride is the 13C and 15N labeled compound of Semicarbazide Hydrochloride. Semicarbazide Hydrochloride has a CAS number of 563-41-7. Semicarbazide is Snow white crystals and used as a reagent for ketones and aldehydes with which it affords crystalline compounds having characteristic melting points.

Aminoguanidine hydrochloride (Hydrazinecarboximidamide) is a diamine oxidase and NO synthase inhibitor, used in the treatment of diabetic nephropathy.

Dibenzothiophene (Imino semicarbazide), a component of petroleum oils, is a sulfur-containing polycyclic aromatic hydrocarbon (PAH) derivate consisting of 3 fused rings with keratolytic activity.

Pimagedine is a prototype therapeutic agent for the prevention of formation of advanced glycation endproducts. Pimagedine reacts rapidly with α,β-dicarbonyl compounds such as methylglyoxal, glyoxal, and 3-deoxyglucosone to prevent the formation of advanced glycation endproducts (AGEs).

4-Cyclohexyl-1-phenylthiosemicarbazide is employed as an intermediate.

1-(3',6'-Bis(ethylamino)-2',7'-dimethyl-3-oxospiro[isoindoline-1,9'-xanthen]-2-yl)-3-phenylthiourea is a useful organic compound for research related to life sciences and the catalog number is T64845.

1-Phenylsemicarbazide is a useful organic compound for research related to life sciences. The catalog number is T67157 and the CAS number is 103-03-7.

2-Nitrobenzaldehyde Semicarbazone is a metabolite marker for the detection of Nitrofurazone, a highly restricted antibiotic. This compound, derived from Semicarbazide, exhibits significant potential in identifying the presence of Nitrofurazone.

BI-1467335 HCl(BI 1467335) is a selective, orally active inhibitor of semicarbazide-sensitive amine oxidase (SSAO) that helps improve chronic obstructive pulmonary disease in mice[2].

2-Nitrobenzaldehyde semicarbazone (13C, 15N2) is utilized in the LC-MS/MS method for semicarbazide analysis.

SSAO inhibitor-2 (Compound 1) can be used in the research of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc. SSAO inhibitor-2 is the inhibitor of semicarbazide-sensitive amine oxidase (SSAO) with IC 50 s <10 nM and 10-100 μM for human SSAO and MAO-A, respectively [1].

Methylamine occurs endogenously from amine catabolism and its tissue levels increase in some pathological conditions, including diabetes. Interestingly, methylamine and ammonia levels are reciprocally controlled by a semicarbazide-sensitive amine oxidase activity that deaminates methylamine to formaldehyde with the production of ammonia and hydrogen peroxide. Methylamine also targets the voltage-operated neuronal potassium channels, probably inducing the release of neurotransmitter(s).

MD 220661 is an inhibitor of semicarbazide-sensitive amine oxidase (SSAO), and a substrate of the enzyme.

SSAO inhibitor-3 (Compound 2) can be used in the study of atherosclerosis, diabetes and its complications, obesity, stroke, chronic kidney disease, retinopathy, chronic obstructive pulmonary disease (COPD), autoimmune diseases, multiple sclerosis, etc. SSAO inhibitor-3 is an inhibitor of semicarbazide-sensitive amine oxidase (SSAO) with IC 50 s of 0.1-10 μM and <10 nM for human AOC1 and SSAO, respectively [1].

PXS-4681A is a powerful, specific, and irreversible inhibitor of semicarbazide-sensitive amine oxidase (SSAO; VAP-1), with an oral activity and a Ki value of 37 nM. It exhibits exceptional selectivity towards related amine oxidases, ion channels, and seven-transmembrane domain receptors. Additionally, PXS-4681A demonstrates potent anti-inflammatory properties.

SSAO inhibitor-1 is a compound that acts as an inhibitor of semicarbazide-sensitive amine oxidase (SSAO). It exhibits anti-inflammatory properties and is commonly employed in research pertaining to liver diseases.